Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative price increase exceeding 20% over two consecutive trading days on December 3 and 4, 2025 [1] Summary by Relevant Sections - Stock Performance The company's stock price increased by over 20% in total during the specified trading days, indicating significant market activity [1] - Self-Examination and Verification The company conducted a self-examination and confirmed that there was no need to correct or supplement previously disclosed information. No undisclosed significant information was found in media reports [1] - Operational Status The company's production and operations are reported to be normal, with no significant matters that should have been disclosed but were not [1] - Insider Trading During the period of abnormal fluctuation, the controlling shareholders did not engage in buying or selling the company's stock, and there were no violations of fair information disclosure regulations [1] - Investor Advisory The company advised investors to make rational investment decisions and to be aware of potential risks [1]
瑞康医药:股票连续两日涨幅偏离值累计超20%现异常波动